



## ASX RELEASE

### Race signs key manufacturing agreement for Bisantrene

**5 October 2016, Perth, Australia:** Race Oncology Ltd (ASX: RAC) is pleased to announce that it has executed a manufacturing and supply agreement with Sai Life Sciences, Ltd.

Under the agreement, Sai will manufacture the Bisantrene API (*Active Pharmaceutical Ingredient*) for Race. Under the initial project scope, Sai will supply sufficient API to support at least the first year of sales of Bisantrene under the Company's proposed Named Patient Program in Europe. It is also expected to provide enough API for the additional clinical studies that may be required to support the Company's US FDA approval. Beyond the initial manufacturing program, it is the intention that Sai will become Race's long term API manufacturer to support global sales of Bisantrene.

"Sai is an important strategic supply partner for Race," said Managing Director, Peter Molloy. "Their reputation and ability to produce GMP API according to Race's timeline and at a competitive cost have been important considerations." Mr Molloy added: "The decision to commence manufacturing is an important one for the Company overall; it signals our full commitment to now drive forward towards the launch of Bisantrene."

The initial API manufacturing will take several months to complete and is the first step in the production of the final Bisantrene product for sale or clinical use. Once successfully produced, the API will be shipped by Sai to another GMP manufacturer (yet to be selected and announced by Race) that will undertake the final drug formulation and packaging for sale.

#### **About Sai Life Sciences Ltd**

Based in Hyderabad (India), Sai Life Sciences is a contract research, development and manufacturing organisation focused on accelerating discovery, development and commercial supply of pharmaceuticals. Sai Life Sciences supplies 7 of the top 15 pharma companies, as well as several large biotech firms. In the past 10 months, Sai Life Sciences has successfully passed 4 US FDA audits and 1 Japanese PMDA audit across 4 of its facilities. Visit [sailife.com](http://sailife.com) for more information.

#### **About Race Oncology**

Race Oncology Ltd is a specialty pharmaceutical company, whose business model is to pursue later stage assets, principally in the cancer field. The Company's first important asset is a chemotherapy drug, called Bisantrene, which was the subject of more than 40 phase II clinical studies during the 1980s and 1990s. Race Oncology owns recent patent filings on Bisantrene and has secured Orphan Drug Designation in the US. The Company's goal is to complete final development of Bisantrene and bring this valuable cancer drug to market. Visit [raceoncology.com](http://raceoncology.com) for more information.

For more information:

**Peter Molloy**  
Managing Director

T: +61 (0) 3 9097 1656  
M: +61 (0) 418 174 816  
E: [plmolloy@raceoncology.com](mailto:plmolloy@raceoncology.com)